Aug. 5 at 2:13 PM
$SNDX (L @ 7.5% PW, +109% gain)
Nice red to green move as market digests Q2 call
Revuforj likely losing share in NPM1, but positives outweigh the negative as post-transplant use increases (longer duration, revenues will stack nicely going forward)
Net loss down 44%, inching closer to break-even
Reiterated
$2B+ peak sales in US alone for Revuforj
NUP98r adds another 1,000 to 2,000 patients, can be accessed efficiently via inclusion in NCCN guidelines
15% of NPM1 patients have received a menin inhibitor, expect that to increase to 30% next year
